$SMLR
Semler Scientific, Inc.

2022 Q3 Form 10-Q Financial Statement

#000155485922000020 Filed on August 05, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $14.05M $14.83M $14.02M
YoY Change 0.4% 3.61% 6.32%
Cost Of Revenue $1.138M $963.0K $970.0K
YoY Change -17.66% -3.31% -38.57%
Gross Profit $12.91M $13.87M $13.05M
YoY Change 2.38% 4.13% 12.43%
Gross Profit Margin 91.9% 93.51% 93.08%
Selling, General & Admin $7.198M $7.613M $7.978M
YoY Change 13.89% 28.95% 63.08%
% of Gross Profit 55.76% 54.91% 61.15%
Research & Development $1.244M $1.074M $1.126M
YoY Change 20.08% 13.41% 62.48%
% of Gross Profit 9.64% 7.75% 8.63%
Depreciation & Amortization $153.0K $154.0K $46.00K
YoY Change 212.24% 250.0% 6.98%
% of Gross Profit 1.19% 1.11% 0.35%
Operating Expenses $7.198M $7.613M $7.978M
YoY Change 13.89% 28.95% 63.08%
Operating Profit $4.467M $5.178M $3.942M
YoY Change -14.96% -19.89% -34.51%
Interest Expense $137.0K $13.00K $1.000K
YoY Change 4466.67% 333.33% -66.67%
% of Operating Profit 3.07% 0.25% 0.03%
Other Income/Expense, Net $134.0K $13.00K $1.000K
YoY Change 3250.0% 44.44% 0.0%
Pretax Income $4.601M $5.191M $3.943M
YoY Change -12.48% -19.81% -34.5%
Income Tax $926.0K $1.117M $583.0K
% Of Pretax Income 20.13% 21.52% 14.79%
Net Earnings $3.675M $4.074M $3.360M
YoY Change -11.45% -39.08% -31.11%
Net Earnings / Revenue 26.16% 27.48% 23.97%
Basic Earnings Per Share $0.55 $0.60 $0.50
Diluted Earnings Per Share $0.46 $0.51 $0.41
COMMON SHARES
Basic Shares Outstanding 6.800M 6.761M 6.778M
Diluted Shares Outstanding 7.940M 8.029M 8.116M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $45.54M $40.03M $38.43M
YoY Change 26.74% 40.41% 45.12%
Cash & Equivalents $45.54M $40.03M $38.43M
Short-Term Investments
Other Short-Term Assets $1.960M $2.768M $6.033M
YoY Change -55.51% -51.91% 241.04%
Inventory $511.0K $524.0K $595.0K
Prepaid Expenses
Receivables $3.673M $5.544M $5.416M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $51.68M $48.87M $50.47M
YoY Change 12.12% 19.97% 51.63%
LONG-TERM ASSETS
Property, Plant & Equipment $2.621M $2.644M $2.358M
YoY Change 579.02% 543.31% 571.79%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $2.000M $2.000M $821.0K
YoY Change 143.61% 143.61% -73.09%
Other Assets $2.267M $2.292M $313.0K
YoY Change 542.21% 514.48% -20.15%
Total Long-Term Assets $9.239M $8.769M $4.965M
YoY Change 89.4% 66.84% -32.55%
TOTAL ASSETS
Total Short-Term Assets $51.68M $48.87M $50.47M
Total Long-Term Assets $9.239M $8.769M $4.965M
Total Assets $60.92M $57.64M $55.44M
YoY Change 19.51% 25.33% 36.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $483.0K $463.0K $375.0K
YoY Change 20.45% -7.4% -20.21%
Accrued Expenses $6.653M $5.237M $4.383M
YoY Change 25.43% 18.46% 26.06%
Deferred Revenue $1.158M $981.0K $980.0K
YoY Change 27.39% 9.49% -6.58%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $8.385M $6.763M $5.819M
YoY Change 25.28% 14.72% 14.71%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $182.0K $203.0K $224.0K
YoY Change -31.58% -29.02% -26.56%
Total Long-Term Liabilities $182.0K $203.0K $224.0K
YoY Change -31.58% -29.02% -26.56%
TOTAL LIABILITIES
Total Short-Term Liabilities $8.385M $6.763M $5.819M
Total Long-Term Liabilities $182.0K $203.0K $224.0K
Total Liabilities $8.567M $6.966M $6.043M
YoY Change 23.11% 12.7% 12.37%
SHAREHOLDERS EQUITY
Retained Earnings $36.00M $32.33M $28.26M
YoY Change 53.94% 68.05% 125.14%
Common Stock $7.000K $7.000K $7.000K
YoY Change 0.0% 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares $67.95K
Shareholders Equity $52.35M $50.67M $49.39M
YoY Change
Total Liabilities & Shareholders Equity $60.92M $57.64M $55.44M
YoY Change 19.51% 25.33% 36.38%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income $3.675M $4.074M $3.360M
YoY Change -11.45% -39.08% -31.11%
Depreciation, Depletion And Amortization $153.0K $154.0K $46.00K
YoY Change 212.24% 250.0% 6.98%
Cash From Operating Activities $8.021M $6.230M $1.502M
YoY Change 5.03% 188.96% -67.39%
INVESTING ACTIVITIES
Capital Expenditures -$491.0K -$602.0K $122.0K
YoY Change 116.3% 278.62% -8.27%
Acquisitions
YoY Change
Other Investing Activities $0.00 -$1.179M
YoY Change
Cash From Investing Activities -$491.0K -$1.781M -$256.0K
YoY Change 116.3% 1020.13% 18.52%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $99.00K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -2.025M -2.844M -143.0K
YoY Change -22600.0% -8000.0% -1688.89%
NET CHANGE
Cash From Operating Activities 8.021M 6.230M 1.502M
Cash From Investing Activities -491.0K -1.781M -256.0K
Cash From Financing Activities -2.025M -2.844M -143.0K
Net Change In Cash 5.505M 1.605M 1.103M
YoY Change -25.8% -21.05% -74.93%
FREE CASH FLOW
Cash From Operating Activities $8.021M $6.230M $1.502M
Capital Expenditures -$491.0K -$602.0K $122.0K
Free Cash Flow $8.512M $6.832M $1.380M
YoY Change 8.24% 195.12% -69.15%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q2 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
1074000
CY2021Q2 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
947000
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
2200000
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
1640000
CY2022Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
4201000
CY2021Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3622000
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
2945000
us-gaap Stock Issued During Period Value Employee Stock Ownership Plan
StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
673000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
45000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2708000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
8878000
smlr Taxes Paid Related To Net Share Settlement Of Equity Awards
TaxesPaidRelatedToNetShareSettlementOfEquityAwards
-114000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
72000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3000
us-gaap Net Income Loss
NetIncomeLoss
7434000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
6439000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3412000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2282000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6715000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4358000
CY2022Q2 us-gaap Costs And Expenses
CostsAndExpenses
9650000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
50670000
CY2021Q2 us-gaap Costs And Expenses
CostsAndExpenses
7847000
us-gaap Costs And Expenses
CostsAndExpenses
19725000
us-gaap Costs And Expenses
CostsAndExpenses
15012000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
5178000
us-gaap Profit Loss
ProfitLoss
7434000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
6464000
us-gaap Operating Income Loss
OperatingIncomeLoss
9120000
us-gaap Operating Income Loss
OperatingIncomeLoss
12482000
CY2022Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
13000
CY2021Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
3000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
14000
us-gaap Profit Loss
ProfitLoss
11565000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
6000
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
6000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
13000
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
9000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
14000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
11000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
5191000
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
6473000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
9134000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
12493000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1117000
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-215000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1700000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
928000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
4074000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
6688000
us-gaap Net Income Loss
NetIncomeLoss
7434000
us-gaap Net Income Loss
NetIncomeLoss
11565000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.60
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.10
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.72
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6761050
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6702258
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6769552
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6706678
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.51
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.83
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.92
us-gaap Depreciation And Amortization
DepreciationAndAmortization
309000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
310000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.42
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8029302
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8092459
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8071509
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8130971
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
40031000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
37323000
CY2022Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
71000
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
61000
CY2022Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5544000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3619000
CY2022Q2 us-gaap Inventory Net
InventoryNet
524000
CY2021Q4 us-gaap Inventory Net
InventoryNet
550000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2768000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4044000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-160000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
445000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
48867000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
45536000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
6432000
CY2022Q2 us-gaap Property Subject To Or Available For Operating Lease Net
PropertySubjectToOrAvailableForOperatingLeaseNet
1816000
us-gaap Gain Loss On Sale Of Leased Assets Net Operating Leases
GainLossOnSaleOfLeasedAssetsNetOperatingLeases
-215000
CY2021Q4 us-gaap Property Subject To Or Available For Operating Lease Net
PropertySubjectToOrAvailableForOperatingLeaseNet
1643000
CY2022Q2 us-gaap Property Plant And Equipment Excluding Lessor Asset Under Operating Lease After Accumulated Depreciation
PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAfterAccumulatedDepreciation
555000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
4074000
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001554859
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2022Q2 us-gaap Operating Lease Liability Statement Of Financial Position Extensible List
OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
CY2020Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P61M
CY2022Q2 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent
CY2022Q2 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent
CY2022Q2 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
CY2021Q4 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent
CY2021Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent
CY2021Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
CY2020Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P61M
CY2022Q2 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P3Y3M
us-gaap Operating Lease Income Comprehensive Income Extensible List
OperatingLeaseIncomeComprehensiveIncomeExtensibleList
http://fasb.org/us-gaap/2022#Revenues
CY2021Q2 us-gaap Operating Lease Income Comprehensive Income Extensible List
OperatingLeaseIncomeComprehensiveIncomeExtensibleList
http://fasb.org/us-gaap/2022#Revenues
us-gaap Operating Lease Income Comprehensive Income Extensible List
OperatingLeaseIncomeComprehensiveIncomeExtensibleList
http://fasb.org/us-gaap/2022#Revenues
CY2022Q2 us-gaap Operating Lease Income Comprehensive Income Extensible List
OperatingLeaseIncomeComprehensiveIncomeExtensibleList
http://fasb.org/us-gaap/2022#Revenues
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36305
dei Entity Registrant Name
EntityRegistrantName
SEMLER SCIENTIFIC, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-1367393
dei Entity Address Address Line1
EntityAddressAddressLine1
2340-2348 Walsh Avenue, Suite 2344
dei Entity Address City Or Town
EntityAddressCityOrTown
Santa Clara
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
95051
CY2021Q4 us-gaap Property Plant And Equipment Excluding Lessor Asset Under Operating Lease After Accumulated Depreciation
PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAfterAccumulatedDepreciation
394000
CY2022Q2 us-gaap Long Term Investments
LongTermInvestments
821000
CY2021Q4 us-gaap Long Term Investments
LongTermInvestments
821000
CY2022Q2 us-gaap Notes And Loans Receivable Net Noncurrent
NotesAndLoansReceivableNetNoncurrent
1179000
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2292000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
332000
CY2022Q2 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
2106000
CY2021Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
1946000
CY2022Q2 us-gaap Assets
Assets
57636000
CY2021Q4 us-gaap Assets
Assets
50672000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
463000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
443000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5237000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3436000
CY2022Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
981000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
921000
CY2022Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
82000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
80000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
6763000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4880000
CY2022Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
203000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
245000
CY2022Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
203000
CY2021Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
245000
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6864625
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6824380
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6697661
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
50670000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
45547000
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6758458
CY2022Q2 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
166964
CY2021Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
65922
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
7000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
7000
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
18334000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
20645000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
32329000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
24895000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
50670000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
45547000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
57636000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Ownership Plan
StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
45000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
50672000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
35268000
CY2021Q2 smlr Exercise Of Put Option In Private Company Value
ExerciseOfPutOptionInPrivateCompanyValue
2230000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
35000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
47000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
6688000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
39808000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
29793000
smlr Exercise Of Put Option In Private Company Value
ExerciseOfPutOptionInPrivateCompanyValue
2230000
us-gaap Stock Issued During Period Value Employee Stock Ownership Plan
StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
537000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
45000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
98000
us-gaap Net Income Loss
NetIncomeLoss
11565000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
39808000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
49392000
dei City Area Code
CityAreaCode
877
dei Local Phone Number
LocalPhoneNumber
774-4211
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
SMLR
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q2 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
2846000
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
6799703
CY2022Q2 us-gaap Revenues
Revenues
14828000
CY2021Q2 us-gaap Revenues
Revenues
14311000
us-gaap Revenues
Revenues
28845000
us-gaap Revenues
Revenues
27494000
CY2022Q2 us-gaap Cost Of Revenue
CostOfRevenue
963000
CY2021Q2 us-gaap Cost Of Revenue
CostOfRevenue
996000
us-gaap Cost Of Revenue
CostOfRevenue
1932000
us-gaap Cost Of Revenue
CostOfRevenue
2575000
CY2022Q2 smlr Taxes Paid Related To Net Share Settlement Of Equity Awards
TaxesPaidRelatedToNetShareSettlementOfEquityAwards
-8000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
10000
us-gaap Gain Loss On Sale Of Leased Assets Net Operating Leases
GainLossOnSaleOfLeasedAssetsNetOperatingLeases
-124000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
38000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
9000
us-gaap Share Based Compensation
ShareBasedCompensation
676000
us-gaap Share Based Compensation
ShareBasedCompensation
635000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1962000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1952000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-26000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1375000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1276000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4381000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
1960000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-45000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
20000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-177000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1800000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1625000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-40000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-44000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
60000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-67000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
7732000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
6762000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
258000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
237000
us-gaap Payments To Acquire Notes Receivable
PaymentsToAcquireNotesReceivable
1179000
us-gaap Payments To Acquire Equipment On Lease
PaymentsToAcquireEquipmentOnLease
600000
us-gaap Payments To Acquire Equipment On Lease
PaymentsToAcquireEquipmentOnLease
138000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2037000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-375000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
114000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
2945000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
72000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
45000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2987000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37323000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
22079000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
40031000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
28511000
us-gaap Basis Of Accounting
BasisOfAccounting
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">1.           Basis of Presentation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Semler Scientific, Inc., a Delaware corporation (“Semler” or “the Company”), prepared the unaudited interim financial statements included in this report in accordance with United States generally accepted accounting principles (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. As such, the information included in this quarterly report on Form 10-Q should be read in conjunction with the audited financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2021 filed with the SEC on March 4, 2022 (the “Annual Report”). In the opinion of management, these financial statements include all adjustments (consisting of normal recurring adjustments) necessary for a fair statement of the financial position, results of operations and cash flows for the periods presented. The results of operations for the interim periods shown in this report are not necessarily indicative of the results that may be expected for any future period, including the full year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;"> COVID-19</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In 2021, variable fee license revenues (fee-per-test), which grew strongly in the first half of 2021, decreased subsequently in the second half of 2021. The Company believes this new pattern in the home-testing market is due to a COVID-19 related timing change in the behavior of insurance plans when ordering QuantaFlo testing from its health risk assessment customers. However, the Company does not know if this newly observed pattern will continue in 2022 or in future years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The extent and duration of the pandemic is unknown, and the future effects on the Company’s business are uncertain and difficult to predict. The Company is continuing to monitor the events and circumstances surrounding the COVID-19 pandemic, which may require adjustments to the Company’s estimates and assumptions in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Recently Issued Accounting Pronouncements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Accounting Pronouncements Recently Adopted</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:6pt 0pt 10pt 0pt;">In May 2021, the financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2021-04, Earnings Per Share (Topic 260), Debt—<i style="font-style:italic;">Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40) Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options</i>. This update provides guidance for a modification or an exchange of a freestanding equity-classified written call option that is not within the scope of another Topic. This update is effective for the Company’s fiscal years beginning after December 15, 2021. The Company adopted this ASU prospectively effective January 1, 2022 and determined that the adoption of this new accounting standard did not have a material impact on its financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">In July 2021, the FASB issued ASU No. 2021-05, </span><i style="font-style:italic;">Leases (Topic 842): Lessors—Certain Leases with Variable Lease Payments</i><i style="font-style:italic;background:#ffffff;">. </i><span style="background:#ffffff;">This update addresses stakeholders’ concerns by amending the lease classification requirements for lessors to align them with practice under Topic 840. Lessors should classify and account for a lease with variable lease payments that do not depend on a reference index or a rate as an operating lease if both of the following criteria are met: i) </span>The lease would have been classified as a sales-type lease or a direct financing lease in accordance with the classification criteria in paragraphs 842-10-25-2 through 25-3, ii) the lessor would have otherwise recognized a day-one loss. This update is effective for the Company’s <span style="background:#ffffff;">fiscal years beginning after December 15, 2021. </span>The Company adopted this ASU prospectively to the leases that commence or modified on or after January 1, 2022 and determined that the adoption of this new accounting standard did not have a material impact on its financial statements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">In November 2021, the FASB issued ASU No. 2021-10<i style="font-style:italic;">, </i><i style="font-style:italic;background:#ffffff;">Government Assistance (Topic 832): Disclosures by Business Entities</i><span style="background:#ffffff;"> </span><i style="font-style:italic;background:#ffffff;">about Government Assistance</i><span style="background:#ffffff;">. This ASU increases the transparency of government assistance to include the disclosure of (1) the types of assistance, (2) an entity's accounting for the assistance, and (3) the effect of the assistance on an entity's financial statements.</span> <span style="background:#ffffff;">The guidance in ASU 2021-10 is effective for financial statements of all entities, including private companies, for annual </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background:#ffffff;">periods beginning after December 15, 2021, with early application permitted.</span> <span style="background:#ffffff;">Entities are required to provide the new disclosures prospectively for all transactions with a government entity that are accounted for under either a grant or a contribution accounting model and are reflected in the financial statements at the date of initially applying the new amendments, and to new transactions entered into after that date. </span>The Company adopted ASU No. 2021-10 prospectively to the government assistance received after January 1, 2022 and determined that the adoption of this new accounting standard did not have a material impact on its financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Accounting Pronouncements Not Yet Adopted</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In June 2016, the FASB issued ASU No. 2016-13, <i style="font-style:italic;">Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“Topic 326”).</i> This ASU requires timelier recording of credit losses on loans and other financial instruments held. Instead of reserves based on a current probability analysis, Topic 326 requires the measurement of all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. All organizations will now use forward-looking information to better inform their credit loss estimates. Topic 326 requires enhanced disclosures regarding significant estimates and judgments used in estimating credit losses, as well as the credit quality and underwriting standards of an organization’s portfolio. These disclosures include qualitative and quantitative requirements that provide information about the amounts recorded in the financial statements. In addition, Topic 326 amends the accounting for credit losses on available-for-sale debt securities and purchased financial assets with credit deterioration. In April 2019, the FASB issued ASU No. 2019-04, <i style="font-style:italic;">Codification Improvements to Topic 326 Financial Instruments—Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825,</i> <i style="font-style:italic;">Financial Instruments</i>, to introduce amendments which will affect the recognition and measurement of financial instruments, including derivatives and hedging. In May 2019, the FASB issued ASU No. 2019-05, <i style="font-style:italic;">Financial Instruments – Credit Losses (Topic 326); </i>Targeted Transition Relief. The amendments in this ASU provide entities that have certain instruments within the scope of Subtopic 326-20 with an option to irrevocably elect the fair value option in Subtopic 825-10, applied on an instrument-by-instrument basis for eligible instruments upon adoption of Topic 326. This standard and related amendments are effective for the Company’s fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company will adopt the new standard in the first quarter of fiscal year 2023. The Company is evaluating the effect of adopting this new accounting guidance but does not expect adoption will have a material impact on the Company's financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In March 2020, FASB issued ASU No. 2020-03, <i style="font-style:italic;">Codification Improvements to Financial Instruments</i>. This ASU improves and clarifies various financial instruments topics, including the current expected credit losses standard issued in 2016 (ASU No. 2016-13). The ASU includes seven different issues that describe the areas of improvement and the related amendments to GAAP, intended to make the standards easier to understand and apply by eliminating inconsistencies and providing clarifications. The amendments have different effective dates. The issues 1-5 are conforming amendments, which are effective upon issuance of this final update. The Company determined that issues 1-5 have no impact on its financials. The amendments related to issue 6 and 7 effect ASU No. 2016-13, <i style="font-style:italic;">Financial instruments – credit losses (Topic 326): measurement of credit losses on financial statements</i>. Effective dates of issue 6 and 7 are the same as the effective date of ASU No. 2016-13. The Company will adopt the new standard in the first quarter of fiscal year 2023. The Company is evaluating the effect of adopting this new accounting guidance, but does not expect adoption will have a material impact on the Company's financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">In October 2021, the FASB issued ASU No.2021-08, <i style="font-style:italic;">Business Combinations (Topic 805):</i> A<i style="font-style:italic;background:#ffffff;">ccounting for Contract Assets and Contract Liabilities from Contracts with Customers</i>. <span style="background:#ffffff;">This ASU improves the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice and inconsistency related to recognition of an acquired contract liability and payment terms and their effect on subsequent revenue recognized by the acquirer</span>. For public business entities, this guidance will be effective for fiscal years beginning after December 15, 2022 and for interim periods within those fiscal years. For all other entities, this guidance is effective for fiscal years beginning after December 15, 2023 and for interim periods within those fiscal years. This ASU should be applied prospectively to all business combinations in the year of adoption. The Company will adopt the new standard in the first quarter of fiscal year 2023. The Company does not expect the adoption of this standard will have a material impact on its financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In March 2022, the FASB issued ASU No.2022-02, <i style="font-style:italic;">Financial Instruments-Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures, </i>which<i style="font-style:italic;"> </i><span style="white-space:pre-wrap;">eliminates the troubled debt restructuring (“TDR”) accounting model in ASC 310-40 for creditors that have adopted the guidance on measurement of credit losses in ASU 2016-13. Additionally, the ASU requires the public business entities to disclose current period gross writeoffs by year of origination for financing receivables and net investments in leases as part of their vintage disclosures under ASC 326. For entities that have adopted the amendments in ASU 2026-13, the amendments are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. For entities that have not yet adopted the amendments in ASU 2016-13, the effective dates are the same as effective dates in ASU 2016-13. The Company will adopt this ASU along with ASU 2016-13 in the first quarter of 2023. The Company does not expect the adoption of this standard will have a material impact on its financial statements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">​</span></p>
CY2021Q4 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
332000
CY2022Q2 smlr Revenue Recognition From Variable License Fee Contracts
RevenueRecognitionFromVariableLicenseFeeContracts
6012000
CY2021Q2 smlr Revenue Recognition From Variable License Fee Contracts
RevenueRecognitionFromVariableLicenseFeeContracts
6504000
smlr Revenue Recognition From Variable License Fee Contracts
RevenueRecognitionFromVariableLicenseFeeContracts
11855000
smlr Revenue Recognition From Variable License Fee Contracts
RevenueRecognitionFromVariableLicenseFeeContracts
12162000
CY2022Q2 smlr Revenue Recognition From Sales Of Hardware And Equipment Accessories
RevenueRecognitionFromSalesOfHardwareAndEquipmentAccessories
268000
CY2021Q2 smlr Revenue Recognition From Sales Of Hardware And Equipment Accessories
RevenueRecognitionFromSalesOfHardwareAndEquipmentAccessories
188000
smlr Revenue Recognition From Sales Of Hardware And Equipment Accessories
RevenueRecognitionFromSalesOfHardwareAndEquipmentAccessories
553000
smlr Revenue Recognition From Sales Of Hardware And Equipment Accessories
RevenueRecognitionFromSalesOfHardwareAndEquipmentAccessories
520000
CY2022Q2 us-gaap Inventory Net
InventoryNet
524000
CY2021Q4 us-gaap Inventory Net
InventoryNet
550000
CY2022Q2 us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
8548000
CY2021Q2 us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
7618000
us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
16437000
us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
14812000
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2292000
CY2022Q2 us-gaap Property Subject To Or Available For Operating Lease Gross
PropertySubjectToOrAvailableForOperatingLeaseGross
3479000
CY2021Q4 us-gaap Property Subject To Or Available For Operating Lease Gross
PropertySubjectToOrAvailableForOperatingLeaseGross
3241000
CY2022Q2 us-gaap Property Subject To Or Available For Operating Lease Accumulated Depreciation
PropertySubjectToOrAvailableForOperatingLeaseAccumulatedDepreciation
1663000
CY2021Q4 us-gaap Property Subject To Or Available For Operating Lease Accumulated Depreciation
PropertySubjectToOrAvailableForOperatingLeaseAccumulatedDepreciation
1598000
CY2022Q2 us-gaap Property Subject To Or Available For Operating Lease Net
PropertySubjectToOrAvailableForOperatingLeaseNet
1816000
CY2021Q4 us-gaap Property Subject To Or Available For Operating Lease Net
PropertySubjectToOrAvailableForOperatingLeaseNet
1643000
CY2022Q2 us-gaap Operating Leases Income Statement Depreciation Expense On Property Subject To Or Held For Lease
OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease
103000
CY2021Q2 us-gaap Operating Leases Income Statement Depreciation Expense On Property Subject To Or Held For Lease
OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease
110000
us-gaap Operating Leases Income Statement Depreciation Expense On Property Subject To Or Held For Lease
OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease
212000
us-gaap Operating Leases Income Statement Depreciation Expense On Property Subject To Or Held For Lease
OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease
223000
CY2022Q2 smlr Accumulated Depreciation Reduction For Returned Items
AccumulatedDepreciationReductionForReturnedItems
57000
CY2021Q2 smlr Accumulated Depreciation Reduction For Returned Items
AccumulatedDepreciationReductionForReturnedItems
50000
smlr Accumulated Depreciation Reduction For Returned Items
AccumulatedDepreciationReductionForReturnedItems
147000
smlr Accumulated Depreciation Reduction For Returned Items
AccumulatedDepreciationReductionForReturnedItems
191000
CY2022Q2 us-gaap Gain Loss On Sale Of Leased Assets Net Operating Leases
GainLossOnSaleOfLeasedAssetsNetOperatingLeases
-141000
CY2021Q2 us-gaap Gain Loss On Sale Of Leased Assets Net Operating Leases
GainLossOnSaleOfLeasedAssetsNetOperatingLeases
-41000
us-gaap Gain Loss On Sale Of Leased Assets Net Operating Leases
GainLossOnSaleOfLeasedAssetsNetOperatingLeases
-215000
us-gaap Gain Loss On Sale Of Leased Assets Net Operating Leases
GainLossOnSaleOfLeasedAssetsNetOperatingLeases
-124000
CY2022Q2 us-gaap Notes And Loans Receivable Net Noncurrent
NotesAndLoansReceivableNetNoncurrent
1179000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
332000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
273000
CY2022Q2 smlr Miscellaneous Deposit Others
MiscellaneousDepositOthers
19000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
314000
CY2021Q4 smlr Miscellaneous Deposit Others
MiscellaneousDepositOthers
18000
CY2022Q2 us-gaap Property Plant And Equipment Excluding Lessor Asset Under Operating Lease Before Accumulated Depreciation
PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation
1141000
CY2021Q4 us-gaap Property Plant And Equipment Excluding Lessor Asset Under Operating Lease Before Accumulated Depreciation
PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation
882000
CY2022Q2 us-gaap Property Plant And Equipment Excluding Lessor Asset Under Operating Lease Accumulated Depreciation
PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAccumulatedDepreciation
586000
CY2021Q4 us-gaap Property Plant And Equipment Excluding Lessor Asset Under Operating Lease Accumulated Depreciation
PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAccumulatedDepreciation
488000
CY2022Q2 us-gaap Property Plant And Equipment Excluding Lessor Asset Under Operating Lease After Accumulated Depreciation
PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAfterAccumulatedDepreciation
555000
CY2021Q4 us-gaap Property Plant And Equipment Excluding Lessor Asset Under Operating Lease After Accumulated Depreciation
PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAfterAccumulatedDepreciation
394000
CY2022Q2 us-gaap Depreciation Excluding Lessor Asset Under Operating Lease
DepreciationExcludingLessorAssetUnderOperatingLease
51000
CY2021Q2 us-gaap Depreciation Excluding Lessor Asset Under Operating Lease
DepreciationExcludingLessorAssetUnderOperatingLease
44000
us-gaap Depreciation Excluding Lessor Asset Under Operating Lease
DepreciationExcludingLessorAssetUnderOperatingLease
97000
us-gaap Depreciation Excluding Lessor Asset Under Operating Lease
DepreciationExcludingLessorAssetUnderOperatingLease
87000
CY2022Q2 us-gaap Long Term Investments
LongTermInvestments
821000
CY2021Q4 us-gaap Long Term Investments
LongTermInvestments
821000
us-gaap Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount
0
CY2021 us-gaap Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount
0
CY2022Q2 smlr Prepaid Licenses Noncurrent
PrepaidLicensesNoncurrent
2000000
CY2022Q2 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
292000
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3488000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1754000
CY2022Q2 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
1251000
CY2021Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
1159000
CY2022Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
498000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
523000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5237000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3436000
smlr Share Based Payment Arrangement Shares Issued Net Of Shares For Tax Withholdings
ShareBasedPaymentArrangementSharesIssuedNetOfSharesForTaxWithholdings
7900
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
673000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
5400
smlr Share Based Compensation Arrangement By Share Based Payment Award Number Of Non Employees
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfNonEmployees
1
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
537000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
11565000
us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
false
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
22000
CY2021Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
28000
us-gaap Operating Lease Cost
OperatingLeaseCost
44000
us-gaap Operating Lease Cost
OperatingLeaseCost
68000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
44000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
90000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
93000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
71000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
298000
CY2022Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
13000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
285000
CY2022Q2 smlr Operating Lease Expenses In Excess Of Cash Payments
OperatingLeaseExpensesInExcessOfCashPayments
12000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
273000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
273000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
82000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
203000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
314000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
80000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
245000
CY2022Q1 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.50
CY2021Q4 smlr Income Taxes Receivable Cares Act
IncomeTaxesReceivableCaresAct
1240000
CY2022Q1 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
20000000.0
CY2022Q2 us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
99012
CY2022Q2 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
2846000
us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
101042
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
2945000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
9610
smlr Share Based Compensation Arrangement By Share Based Payment Award Number Of Non Employees
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfNonEmployees
1
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1356245
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.30
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y11M19D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
119830000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
33000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.81
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
5000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
30.48
smlr Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm
P4Y
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1328245
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.41
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y6M3D
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
32912000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1323245
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.31
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y5M26D
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
32912000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
48000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
47000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
676000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
635000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
48000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
47000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
676000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
635000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.10
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6706678
CY2022Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.2152
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.1862
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.72
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
69637
smlr Amount Of Dilutive Securities Common Stock Warrants
AmountOfDilutiveSecuritiesCommonStockWarrants
0
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
73643
smlr Amount Of Dilutive Securities Common Stock Warrants
AmountOfDilutiveSecuritiesCommonStockWarrants
0
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1232320
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1117000
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-215000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1700000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
928000
CY2021Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.0332
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0743
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022Q2 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2021Q2 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
419000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
476000
CY2022Q2 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2021 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6761050
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
4074000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.60
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6702258
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
6688000
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.00
CY2022Q2 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
67434
CY2022Q2 smlr Amount Of Dilutive Securities Common Stock Warrants
AmountOfDilutiveSecuritiesCommonStockWarrants
0
CY2021Q2 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
73789
CY2021Q2 smlr Amount Of Dilutive Securities Common Stock Warrants
AmountOfDilutiveSecuritiesCommonStockWarrants
0
CY2022Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1200818
CY2022Q2 us-gaap Amount Of Dilutive Securities Stock Options And Restrictive Stock Units
AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits
0
CY2021Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1316412
CY2021Q2 us-gaap Amount Of Dilutive Securities Stock Options And Restrictive Stock Units
AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits
0
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8029302
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
4074000
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.51
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8092459
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
6688000
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.83
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6769552
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
7434000
us-gaap Amount Of Dilutive Securities Stock Options And Restrictive Stock Units
AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits
0
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1350650
us-gaap Amount Of Dilutive Securities Stock Options And Restrictive Stock Units
AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits
0
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8071509
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
7434000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.92
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8130971
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
11565000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.42
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0

Files In Submission

Name View Source Status
0001554859-22-000020-index-headers.html Edgar Link pending
0001554859-22-000020-index.html Edgar Link pending
0001554859-22-000020.txt Edgar Link pending
0001554859-22-000020-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
smlr-20220630.xsd Edgar Link pending
smlr-20220630x10q.htm Edgar Link pending
smlr-20220630x10q_htm.xml Edgar Link completed
smlr-20220630xex31d1.htm Edgar Link pending
smlr-20220630xex31d2.htm Edgar Link pending
smlr-20220630xex32d1.htm Edgar Link pending
smlr-20220630_cal.xml Edgar Link unprocessable
smlr-20220630_def.xml Edgar Link unprocessable
smlr-20220630_lab.xml Edgar Link unprocessable
smlr-20220630_pre.xml Edgar Link unprocessable